U.S. Active Pharmaceutical Ingredients Market

U.S. Active Pharmaceutical Ingredients Market Size (2023 to 2028)

The U.S. Active Pharmaceutical Ingredients Market size is estimated to grow at a CAGR of 10.24% between 2023 and 2028.

Significantly growing drug research and development provide multiple opportunities for manufacturers to introduce advanced active pharmaceutical products. API in a drug is specifically used for treating, diagnosing, mitigating, or preventing human health problems. Also, it significantly affects the body's physiological functions, repairing, changing, or altering them, which is more likely to impact market growth positively. Active Pharmaceutical ingredients have a wide range of applications in the pharmaceutical industry, including oncology, central nervous system disorders, diabetes, neurological disorders, cardiovascular disease, pulmonary disease, and so on, which creates U.S. Active Pharmaceutical Ingredients Market growth.  

Favorable government policies for API development, increasing incentives, and investment by private and government organizations in the United States are likely to increase the market growth. Furthermore, since ADCs are essential and effective cancer therapy modalities combined with clinically active drugs and monoclonal antibodies, the development of cancer-specific APIs is expected to propel the U.S. API market even further.

Active pharmaceutical component manufacturers must make costly investments to update their manufacturing facilities to meet requirements such as c GMP, which is a significant challenge for market growth. In addition, API chemical synthesis also requires costly and rare building blocks and raw materials, further increasing API manufacturing costs.

Impact of COVID-19 on the U.S. Active Pharmaceutical Ingredients Market:

The emergence of the COVID-19 pandemic in 2020 has had a positive impact on the market. Countries and significant players are producing massive quantities of ingredients to meet the demand for COVID-19 treatment. However, during the first half of 2022, the market had a downfall in U.S. active pharmaceutical ingredients market. The virus has impacted the United States drug supply chain and manufacturing of pharmaceutical products due to a lack of workforce. However, to remain competitive in the market, large companies in the united states are introducing emerging technology and launching new products. Mergers and acquisitions, as well as innovative product growth, are examples of competitive strategies. Pfizer (U.S.), for instance, signed a multi-year deal with Gilead Sciences Inc. in 2020 to manufacture and supply Gilead's antiviral medication (Remdesivir) for the treatment of COVID-19. Due to the COVID-19 outbreak, drug companies have redirected their models to focus on a larger consumer pool.

This research report on the U.S. active pharmaceutical ingredients market has been segmented and sub-segmented into the following categories.

By Type of Manufacturing Process:

• Captive Manufacturing
• Contract Manufacturing

By Type of Synthesis:

• Synthetic
• Biotech

By API Formulation:

• Generic API
• Innovative API

By Application:

• Cardiovascular Diseases
• Oncology
• Neurological Disorders
• Orthopedic Disorders
• Respiratory
• Gastrointestinal Disorders
• Urology
• Others

By Molecule:

• Large Molecule
• Small Molecule

By Country:

• The United States

The United States recorded the largest market share of active pharmaceutical ingredients in 2022 in the global market, and it is expected to continue to grow further during the forecast period. Increased technological advancements would boost market players' capabilities and manufacturing expertise, allowing them to supply APIs in bulk to meet consumer demand, thereby propelling the active pharmaceutical ingredients (API) market. In addition, the growing prevalence of preventable chronic diseases, increased government emphasis on generic drugs, and the demand for biologics and specialty medicines contribute to the United States' vast share of the North American market. The united states market growth has significantly increased over the years as Large firms in the United States are adopting digital technologies and releasing new goods to remain competitive. Mergers and acquisitions, as well as the creation of new products, are examples of competitive strategies.

KEY MARKET PLAYERS:

Companies such as Sanofi, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc (GSK), Novartis AG, Eli Lilly and Company, and Teva Pharmaceutical Industries Ltd are playing a significant role in the U.S. active pharmaceutical ingredients market.